HOME >> BIOLOGY >> NEWS
Anti-HIV drugs save vision, improve outlook for AIDS patients

A new study from Johns Hopkins researchers shows the multiple anti-HIV drug regimen called highly active antiretroviral therapy (HAART) saves eyesight as well as lives. A second study led by Johns Hopkins researchers finds that among AIDS patients with longstanding vision problems, those who took HAART reported higher overall quality of life.

The Johns Hopkins team reported in the April issue of Archives of Ophthalmology that AIDS patients who received HAART had a 75 percent lower risk of visual impairment than those who did not. In the second, multicenter study, published in the May issue of the journal Ophthalmology, AIDS patients with vision loss reported a lower vision-related quality of life, although those who took HAART reported higher overall quality of life than those who did not.

AIDS patients are at high risk of vision loss from cytomegalovirus (CMV) retinitis, an infectious disease of the retina. Symptoms include "floaters" and permanent loss of central vision. With HAART, which became available in 1995, many patients' immune systems seem to recover enough to control CMV retinitis. The condition at one time affected 30 percent of patients at some point during their lives, but has probably decreased to 7.5 percent with the advent of HAART, says John H. Kempen, M.D., Ph.D., lead author of both studies and assistant professor of ophthalmology and epidemiology. By the time CMV is diagnosed, Kempen says, many AIDS patients are already legally blind or have significant vision loss.

"AIDS patients should take HAART as soon as and as much as they can," he says. "HAART often can save both their life and their vision."

In the Archives study, Kempen and his team evaluated 648 AIDS patients seen at the Wilmer Eye Institute at Johns Hopkins between August 1983 and March 2000. Seventeen percent had 20/200 vision (the definition of legal blindness) at the time of diagnosis, while 33 percent had 20/50 vision -- poor eno
'"/>

Contact: Karen Blum
kblum@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
13-May-2003


Page: 1 2 3

Related biology news :

1. Anti-HIV statisticians win $1.125 million NIH Merit Award
2. New Anti-HIV Therapies Needed To Eradicate HIV
3. Tiny molecules have big potential as cancer drugs, Stanford researcher believes
4. New and better drugs for tuberculosis goal of UH professor
5. New technique helps scientists reveal interactions between genes and drugs
6. New database to help develop AIDS drugs
7. Orange, tangerine peels could be better than drugs for lowering cholesterol
8. New papillomavirus target could lead to specific antiviral drugs for precancerous cervical lesions
9. Newer drugs more effective at curing strep throat than penicillin
10. New software developed at Rensselaer predicts promising ingredients for new drugs
11. Protein abundant in human tumors confers resistance to anticancer drugs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 24, 2020 , ... Elgia ... inflammatory and fibrotic diseases, today announced that Dr. Stacie Canan has joined the ... Dr. Canan previously served as Executive Director of Global Health at Bristol Myers ...
(Date:8/23/2020)... (PRWEB) , ... August 21, 2020 , ... ... Rigaku Corporation has been published and is now available on the company’s ... X-ray diffraction—serves the X-ray analysis community, presenting current news and crystallographic research. ...
(Date:8/21/2020)... (PRWEB) , ... August 20, 2020 , ... ... that Hassan Movahhed , a Clinical Operations executive with expertise in clinical ... has joined the firm as an Expert Consultant. Throughout his career, Mr. Movahhed ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... ... September 01, 2020 , ... Slone ... companies, has announced the placement of Julianne Averill , CPA, as Chief ... all financial operations and implementing key business strategies to accelerate Alveo’s growth as ...
(Date:8/15/2020)... ... August 13, 2020 , ... True Terpenes , the leading platform ... Advisory Board (SAB) to research the medical potential of terpenes and the potential ... with terpenes. The board is focused on expanding the recently launched line of effects-based ...
(Date:8/12/2020)... Mass. (PRWEB) , ... August 11, 2020 , ... ... $300,000 a year to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research ... in 2021 and 2022. The network is a consortium of academic research centers ...
(Date:8/12/2020)... Mich. (PRWEB) , ... August 12, 2020 , ... ... Group, Inc. (EMMA International), a global leader in FDA compliance consulting has ... the nation’s fastest-growing private companies. The list represents a unique look at the ...
Breaking Biology Technology:
Cached News: